Skip to main content

Table 1 Improved BFM protocols at our institution

From: ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol

Treatment and medicine

Dose

Time

Induction and re-induction therapy

 CODPL

  DEX or Pred

10 mg/m2(maximum:10 mg) or 60 mg/m2(maximum:60 mg)

d1–28(reduction in 1 week)

  VCR

1.5 mg/m2(maximum:2 mg)

d1, 8, 15, 22

  CTX

1 g/m2

d1

  DNR or IDR

40-60 mg/m2 or 8-10 mg/m2

d1, 8

  L-asp

10,000 U/m2

d15, 17, 19, 21, 23, 25, 27, 29, 31, 33

Consolidation therapy

 HDMTX×2

  HDMTX

2.5–3.5 g/m2

d1, 22

  VCR

1.5 mg/m2

d1, 8, 15, 22

  DNR or IDR

40-60 mg/m2 or 8-10 mg/m2

d8, 10

 HDMTX

  HDMTX

2.5–3.5 g/m2

d1

  VCR

1.5 mg/m2

d1

 HDAra-C

  HDAra-C

2 g/m2

d1–3

  DNR or IDR

40-60 mg/m2 or 8-10 mg/m2

d2–3

 IFO

  IFO

1 g/m2

d1–5

  VP-16

100 mg/m2

d3–5

  VCR

1.5 mg/m2

d1

 Maintenance therapy

  6-MP

50 mg/m2

once a day

  MTX

20 mg/m2

once a week

  1. DEX dexamethasone, Pred prednisone, VCR vincristine, CTX cyclophosphamide, DNR daunomycin, IDR idarubicin, L-asp native Escherichia coli L- asparaginase, HDMTX high dose methotrexate, HDAra-C high dose cytarabine, IFO ifosfamide, VP-16 etoposide, 6-MP mercaptopurine